Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report)'s share price was up 38.6% during mid-day trading on Wednesday . The stock traded as high as C$5.56 and last traded at C$5.53. Approximately 231,254 shares changed hands during trading, an increase of 139% from the average daily volume of 96,646 shares. The stock had previously closed at C$3.99.
Wall Street Analyst Weigh In
A number of research firms have recently commented on MDP. Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the company a "speculative buy" rating in a research note on Monday, September 30th. Stifel Nicolaus upped their price target on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. Raymond James upgraded Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price target for the company in a report on Wednesday, January 8th. Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 17th. Finally, Alliance Global Partners upgraded Medexus Pharmaceuticals to a "strong-buy" rating in a report on Monday, December 23rd. Two research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Strong Buy" and a consensus price target of C$5.58.
Read Our Latest Research Report on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Performance
The stock's 50 day simple moving average is C$3.04 and its 200 day simple moving average is C$2.66. The firm has a market cap of C$110.14 million, a P/E ratio of 89.80 and a beta of 1.96.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
